

SENISCA announces changes to the Leadership Team as the Company Continues to Evolve Rapidly.

SENISCA today announces the planned departure of SENISCA's Co-founder and COO, Kirsty Semple, effective June 26th, 2024.

Kirsty led the Company between 2020-2023 and had a significant impact on establishing and shaping the Company through the initial phases of development as launch CEO. Since incorporation, SENISCA has successfully raised £7.1M in equity financing, with an additional £1.1M coming from non-dilutive and commercial revenues. This financing reflects the effective leadership of the Company, developing impactful strategies to realise the potential of SENISCA's disruptive platform technology, together with the creation of a world-leading team ([Reverse Cell Ageing - Senisca](#)) and the generation of cutting-edge foundational data.

As SENISCA continues its evolution, the planned changes to management are designed to support the company's innovative approach to the treatment of specific diseases of ageing, enabling further growth in terms of bringing additional biopharma expertise within the team to drive the successful delivery of the near-term corporate strategy as the Company heads towards Series A funding.

CEO, Sarah Cole commented "I would like to extend my deep gratitude to Kirsty, an impactful and dedicated leader who has made invaluable contributions to SENISCA since the Company's incorporation in late 2020. It has been a pleasure to work closely together over the past year as SENISCA entered an exciting new phase of growth and development. I would like to take this opportunity to wish Kirsty the very best in her future endeavours."

COO, Kirsty Semple commented "I am immensely proud of what I and the team have achieved since SENISCA's incorporation. The Company has developed rapidly across multiple fronts during this time, including rapid progress in R & D and the expansion of senior leadership to include significant biopharma. expertise. I wish Sarah and the team every success in unlocking the significant potential of SENISCA's senotherapeutic platform during the next exciting phase of company evolution."

END